Manufacturing Chemist Stand Side with Ezi-Dock Systems

Published: 21-May-2024
Manufacturing

We discover what exhibitors at Interphex NYC 2024 are showcasing LIVE!

This article is sponsored by Ezi-Dock Systems

In this interview, Manufacturing Chemist Stand Side speaks with Ezi-Dock Systems, exhibiting at Interpex NYC 2024.

For more interviews with leading companies from across the pharmaceutical manufacturing industry, visit our YouTube channel  and hit subscribe.

Manufacturing Chemist Stand Side...

'Manufacturing Chemist Stand Side' is a series of exclusive video interviews with leading companies in the beauty and personal care industry, conducted during key cosmetic industry events by our award-winning B2B team.

For more information on how you can be part of 'Manufacturing Chemist Stand Side' contact Brian Lubieniecki-Heyburn on +44 2071938253 or via email at brianh@hpcimedia.com.

This interview was led by Brian Lubieniecki-Heyburn Head of Sales at Manufacturing Chemist.

  • Companies:
  • Ezi-Dock Systems
See more

You may also like

Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

Read more
The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
  3. Navigating biologics chemistry, manufacturing and controls with an innovative CDMO Drug development is a journey. From the initial discovery of a druggable target through to commercialisation, biopharma companies face an uphill battle when designing, optimising and advancing safe and efficacious drugs
  4. GSK licenses Touchlight's enzymatic dbDNA for optimised mRNA vaccine production GSK will now have non-exclusive rights to the use of dbDNA for efficient commercial DNA and mRNA production
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

You may also like

Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA
Manufacturing

Process development and clinical manufacturing

Process development & cGMP contract manufacturing for biologics and cell therapies
Manufacturing

KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection

The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Manufacturing

Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues

The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Manufacturing

Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA

The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Manufacturing

GSK licenses Touchlight's enzymatic dbDNA for optimised mRNA vaccine production

GSK will now have non-exclusive rights to the use of dbDNA for efficient commercial DNA and mRNA production
Manufacturing

Why the UK needs to do more to prepare for the “RNA boom”

The UK was a world leader in RNA production during COVID … but the CPI warns that the country needs to do more to maintain this status moving forward
Subscribe now